Abstract As of April 20, 2020, over time, the COVID‐19 pandemic has resulted in 157 970
deaths out of 2 319 066 confirmed cases, at a Case Fatality Rate of~ 6.8%. With the …

Background: Coronavirus disease 19 (COVID-19) can develop into a severe respiratory
syndrome that results in up to 40% mortality. Acute lung inflammatory edema is a major …

Most striking observations in COVID-19 patients are the hints on pulmonary edema (also
seen on CT scans as ground glass opacities), dry cough, fluid restrictions to prevent more …

The COVID‐19 pandemic is rapidly spreading, and health care systems are being
overwhelmed with the huge number of cases, with a good number of cases requiring …

Bradykinin, a member of the kallikrein–kinin system (KKS), is a potent, short-lived vasoactive
peptide that acts as a vasodilator and an inflammatory mediator in a number of signaling …

COVID-19 patients can present with pulmonary edema early in disease. We propose that
this is due to a local vascular problem because of activation of bradykinin 1 receptor (B1R) …

Neither the disease mechanism nor treatments for COVID-19 are currently known. Here, we
present a novel molecular mechanism for COVID-19 that provides therapeutic intervention …

The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 9.2 million …

The novel coronavirus disease 2019 (COVID-19) is a rapidly expanding infection around the
world. The world Health Organization (WHO) in March 2020 announced the Coronavirus …

Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) virus has taken an immeasurable toll on humanity, with the …